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Introduction
Pseudohypoaldosteronism type 1 (PHA-1, MIM #264350)
is a rare disease caused by defective transepithelial sodium
transport. Affected patients develop life-threatening, 
neonatal-onset salt loss, hyperkalemia, acidosis, and 
elevated aldosterone levels due to end-organ resistance 
to aldosterone. Accordingly, they are insensitive to 
mineralocorticoid treatment, but respond to high doses of 
sodium supplementation and potassium-lowering therapies. 
A multidisciplinary team including a neonatologist, an 
endocrinologist, a neurologist and a dietician is essential for
evaluation of longitudinal growth and neurological 
development in PHA-1 patients. We would like to share our
experience on the difficulties of the management of a patient
diagnosed in the newborn period with genetically proven 
autosomal recessive PHA-1. 
Case Report
A seven-day-old female baby was brought to the 
emergency department because of jaundice.  The family did
not report any symptoms other than jaundice. The baby was
born to third-degree consanguineous parents at term.  Birth
weight was 3060 g. The baby was reported to be apparently
healthy during the first 6 days of life. 
Physical examination was unremarkable except for mild
lethargy. External genitalia were normal. Initial biochemistry
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revealed an elevated serum indirect bilirubin (24 mg/dL), but
unexpectedly abnormal serum electrolytes (Na: 113 mEq/L
and K: 13 mEq/L), confirmed by double testing. Results of 
urinanalysis, renal functions and renal ultrasound were normal.
Pelvic ultrasound showed normal Mullerian structures. 
The infant was admitted to the neonatal intensive care unit
for hyperbilirubinemia and abnormal electrolytes discordant
with her general well-being.  Intravenous (IV) fluid and sodium
replacement as well as potassium-lowering therapy were
started immediately. Within the following 2-3 hours, the
patient deteriorated rapidly, developed cardiac arrest and
needed  cardiopulmonary resuscitation. The baby  improved
with the above-mentioned aggressive supportive therapy and
was  discharged at 1.5 months of age to be followed on an 
outpatient basis. 
The patient was diagnosed as a case of autosomal 
recessive PHA-1. This diagnosis was established because of
absent glucocorticoid deficiency, very high aldosterone and
renin levels and elevated sweat, salivary and urinary sodium
concentrations [serum aldosteron: 2782.3 pg/ml (normal: 10-
160); renin: 170 ng/ml/hr (normal: 0.5-1.19); sweat sodium 75
mEq/L, saliva sodium: 153 mEq/L, urinary sodium: 94 mEq/L].
The diagnosis was confirmed by genetic analysis showing a
novel IVS8-2A>G mutation in the SCNN1A gene.
Discussion
PHA-1 is a rare disease caused by defective transepithelial
sodium transport due to mutations in the genes encoding α
(SCNN1A),  β (SCNN1B) or γ (SCNN1G) subunit of the 
epithelial Na+ channel (ENaC). Affected patients develop 
life-threatening, neonatal-onset salt loss, hyperkalemia, 
acidosis, and elevated aldosterone levels due to end-organ
resistance to aldosterone. Affected patients require life-long
salt supplementation and dietary manipulations aimed at
reducing potassium levels (1).
We would like to summarize our observations and the 
pitfalls we have encountered in the management of this
patient. The initial phase of treatment during the first 1.5
months of life required almost continuous IV fluid 
administration for the correction of dehydration, severe 
electrolyte imbalances and metabolic acidosis. A fluid intake
up to 350 mL/kg/day was needed, varying in accordance with
the degree of dehydration. Hyponatremia was corrected by IV
therapy (sodium concentration increased to provide up to 50
mEq/kg/day). IV sodium bicarbonate (NaHCO3) infusions up to
8 mEq/kg/day were administered to correct metabolic acidosis
and to improve severe hyperkalemia. Besides sodium 
polystyrene sulphonate resin therapy (6 g/kg/day in 8 doses),
sodium bicarbonate, calcium carbonate and glucose-insulin
infusions (as needed), transient peritoneal dialysis (two 
occasions) for severe hyperkalemia became necessary. The
general well-being of our patient was not disturbed although
the serum potassium levels increased to 10-12 mEq/L.
However, the patient developed cardiac arrest 3-4 hours after
admission despite all the supportive therapy. Therefore, we
concluded that the team should be ready to initiate all invasive
and non-invasive measures, including dialysis preparations, as
soon as the first signs of salt-wasting crisis begin. The 
transient peritoneal dialysis catheter may be maintained until
the electrolyte values stabilize.
In the follow-up of this patient, we have observed flares of
pustules especially in the dependent parts of the body just
before and during the severe salt-wasting attacks. Indeed,
patients with PHA-1 may present with seborrheic dermatitis,
folliculitis or miliaria rubra-like lesions preceding severe 
salt-wasting crises. There is a hypothesis that the secretion of
sweat with elevated sodium chloride concentrations directly
affects the eccrine ducts (2). This finding should alert 
physicians and families about impending salt-wasting crises to
take preventive measures.
After discharge at 1.5 months of age, the infant was 
maintained on oral intake only. The mainstay of the treatment
in PHA-1 should include sodium chloride supplements plus
cation-exchange resins. Our patient required very high 
maintenance doses of sodium chloride, occasionally increased
up to 50 mEq/kg/day and divided in 6-8 doses, and 
cation-exchange resins (6 g/kg/day in 4-6 doses). In these
patients, close serum electrolyte monitoring is needed in the
follow-up. At least twice daily serum electrolyte control is 
fundamental during the salt-losing crises. Metabolic acidosis
can be managed by oral NaHCO3. Our patient also required
such treatment (2 mEq/kg/day NaHCO3 in 4 doses), which
helps to improve the low sodium levels besides correcting the
acidosis. Monitoring of blood pH is essential for the regulation
of the NaHCO3 dosage. Because of the commercial 
unavailability of liquid oral sodium chloride preparations,
we had to use table salt (1 gram of table salt contains 
approximately 17 mEq sodium) that was added as 
fractionated doses to the formula of the baby. Babies may not
tolerate this salt-added formula, they show their dislike and
even may cough or vomit. We have overcome this problem by
feeding the baby upright and giving this food at a time when
she appeared to be most hungry.
We had also problems with cation-exchange resins.
Potassium-binding resins that are commercially available 
generally include sodium and calcium polystyrene sulphonate.
Sodium containing ion-exchange resins should be preferred
both to improve sodium deficit and to prevent iatrogenic
hypercalcemia and hypercalciuria that can be seen in PHA-1
patients (3). Calcium-containing exchange resins may 
augment hypercalciuria and hypercalcemia in PHA-1 patients,
especially when administered in high doses. As a second point
of consideration, they are generally unpalatable and patients
with PHA-1 generally need these drugs in high doses as a 
life-long maintenance treatment. In the newborn period, it is
recommended that potassium polystyrene drugs be 
administered as rectal enema, since oral administration may
cause bowel obstruction. On the other hand, particular care is
needed with rectal administration as excessive dosage or 100
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inadequate dilution could result in impaction of the resin, 
intestinal haemorrhage or in colonic necrosis. This enema
should be retained for at least nine hours. Afterwards the
colon needs to be irrigated to remove the resin. These facts
render both rectal and oral routes unsuitable for such babies.
Once the mixture has been prepared, it should be used
straight away. In our patient, we had to increase the dose of
sodium polystyrene to as high as 16 g/day given in 8 doses in
the newborn period. Rectal enema at this dosage caused 
rectal prolapse in our patient. To overcome the problems with
usage of cation-exchange resins and to manage dangerous
levels of plasma potassium, we had to alternate the 
administration of the resin enterally either by mouth or by
nasogastric tube or as rectal enema.  We had to be extremely
careful in oral or rectal administration to use proper dilutions
according to the baby’s tolerance. We were usually able to
administer the drug by mouth as a suspension in a small
amount of water (3-4 mL per gram of powder), or in a 
sweetened liquid (but not fruit juices, which contain 
potassium). The baby was positioned carefully when ingesting
the resin, in order to avoid aspiration, which might lead to
bronchopulmonary complications. 
Feeding of babies with PHA-1 is also problematic. In 
weaning the baby from breastfeeding, the use of commercial
formulas makes it very difficult to reduce the potassium 
content of the infant’s diet below 1-2 mEq/kg/day.
Comprehensive evaluation by a professional dietician for a
low-potassium diet both during the weaning period and later
with supplementary foods is required. Growth failure is 
frequent in these patients.  
Outpatient follow-up of such patients should inevitably
involve close contact with the family, especially during 
infancy, for monitoring of general health, electrolytes and
weight gain.  This can be accomplished both by clinical visits
and through phone calls or online contact.  Our patient is 
currently 6 months old. We have followed her monthly in the
clinic and weekly via phone-call or internet. These intervals
have been more frequent during periods of acute illness.
The monitoring of growth and neurological development
by a multidisciplinary team is also an important aspect of the
follow-up of PHA-1 patients. At six months of age, our patient
showed a satisfactory physical and neuromotor development
in accordance with respective age references. 
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